How The Travere Therapeutics (TVTX) Story Is Shifting After FSGS Approval And Split Analyst Views [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
Travere Therapeutics just saw its modeled fair value per share move slightly, from US$42.36 to US$42.50, in the latest analyst update. That modest shift sits against a backdrop of Street research where some firms are lifting price targets by about US$3 to US$9 after the FSGS approval, while others are trimming by around US$3 to US$4 as they reassess growth assumptions and execution risk. As you read on, you will see how to track these changing targets and what they might mean for your own view on Travere. Stay updated as the Fair Value for Travere Therapeutics shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Travere Therapeutics. What Wall Street Has Been Saying ?? Bullish Takeaways Several firms including Stifel, Piper Sandler, Citi, Guggenheim, BofA, Wedbush and Canaccord have lifted Travere Therapeutics price targets, with individual moves in the US$3 to US$12 range. This points to a more constructive
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI's Landmark FDA Approval For FSGS [Yahoo! Finance]Yahoo! Finance
- Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Travere Therapeutics (TVTX) was upgraded by Piper Sandler from "neutral" to "overweight". They now have a $49.00 price target on the stock.MarketBeat
- Travere Therapeutics (TVTX) had its price target raised by Canaccord Genuity Group Inc. from $47.00 to $56.00. They now have a "buy" rating on the stock.MarketBeat
TVTX
Earnings
- 2/19/26 - Beat
TVTX
Sec Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- TVTX's page on the SEC website